Covid-19 roundup: Temasek leads a $250M raise for BioN­Tech as first Covid-19 mR­NA vac­cine da­ta looms; Chi­na's ...

5 years ago
Coronavirus

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

5 years ago
R&D
Cell/Gene Tx

J&J scut­tles PhI­II lu­pus pro­gram on failed da­ta analy­sis; No­var­tis pays $345M to re­solve bribery charges

5 years ago
News Briefing

Pre­sent­ed with up­beat Alzheimer's ag­i­ta­tion da­ta, FDA sees an­oth­er 'break­through' in Ax­some's AXS-05

5 years ago
R&D
FDA+

DBV lays off em­ploy­ees, scales down pro­grams af­ter re­ceiv­ing no word from FDA

5 years ago
Pharma
FDA+

In­ovio adds two to the lead­er­ship team; Adri­an Woolf­son is out at Sang­amo

5 years ago
Peer Review

No­var­tis yanks ap­pli­ca­tion from the EMA af­ter reg­u­la­tors say re­searchers nev­er proved ef­fi­ca­cy of their $3.4B dry eye ...

5 years ago
FDA+

Sanofi preps an­oth­er round of lay­offs as new ex­ecs look to slim down the glob­al phar­ma in an on­go­ing re­or­ga­ni­za­tion ...

5 years ago
Pharma

Af­ter 2 de­lays, Zo­genix nabs FDA ap­proval for epilep­sy drug, sets price at 3X its GW Phar­ma com­peti­tor

5 years ago
Pharma
FDA+

Ab­b­Vie’s first post-merg­er Al­ler­gan drug pitch strikes out with the FDA as reg­u­la­tors turn thumbs down on Lu­cen­tis ...

5 years ago
FDA+

No­var­tis-backed Po­sei­da is pack­ing in the cash for its next-gen CAR-T work, adding a $110M ven­ture raise on top of ...

5 years ago
Financing
Cell/Gene Tx

EMA nom­i­nates Emer Cooke as ex­ec­u­tive di­rec­tor to re­place Gui­do Rasi

5 years ago
People

Out of jobs, a pair of ear­ly cell ther­a­py ex­ec­u­tives went to Seoul, came back with a new com­pa­ny, $70M and a plan to ...

5 years ago
Financing
Startups

Covid-19 roundup: Mod­er­na en­lists Catal­ent as man­u­fac­tur­ing part­ner, se­cur­ing fill-fin­ish ca­pac­i­ty for the first 100M ...

5 years ago
Coronavirus

Re­lay and iTeos join IPO del­uge while Ak­ou­os and Fu­sion de­cide they can earn more

5 years ago
Financing

CRISPR Ther­a­peu­tics blue­prints cell ther­a­py man­u­fac­tur­ing site; Re­gen­eron fights back against kick­back claims

5 years ago
News Briefing

Over a decade ago, a dis­as­trous tri­al killed re­search on a po­ten­tial im­munother­a­py. Can a Re­gen­eron bis­pe­cif­ic re­vive ...

5 years ago
R&D

FDA OKs Mer­ck’s heavy­weight Keytru­da for can­cer niche — trig­ger­ing ti­tle fight with the street brawlers at ...

5 years ago
R&D
FDA+

Take­da joins mi­cro­bio­me-fo­cused biotech part­ner's $52.6M raise as it pur­sues more in-house can­cer work

5 years ago
Financing

Sang­amo splits the R from the D in a re­or­ga­ni­za­tion — and bids chief farewell

5 years ago
People
R&D

Yale spin­out re-en­gi­neers an im­munother­a­py GSK, oth­ers once aban­doned

5 years ago
Financing
Startups

Back to the im­munol­o­gy draw­ing board, Ab­b­Vie inks dis­cov­ery deal with old Al­ler­gan part­ner

5 years ago
Deals
Discovery

In an un­ex­pect­ed twist, CSL buys world­wide rights to uniQure's PhI­II he­mo­phil­ia B gene ther­a­py in $2B-plus deal

5 years ago
Deals
Cell/Gene Tx

Ac­celeron promised they had great da­ta on so­tater­cept in late Jan­u­ary. But was it good enough to jus­ti­fy a dou­bling ...

5 years ago
R&D
First page Previous page 828829830831832833834 Next page Last page
A service from the Financial Times